Acrania–Exencephaly–Anencephaly (AEAS) Sequence

Acrania–Exencephaly–Anencephaly sequence (AEAS) describes a step-by-step process that starts very early in pregnancy when the skull bones (the cranial vault) do not form. First, the baby has acrania (no skull bones). Because the brain is exposed to amniotic fluid and mechanical forces, it becomes damaged and appears as exencephaly (brain tissue outside the head). With time, that exposed brain breaks down and the condition progresses to anencephaly (most of the brain and skull are absent). This is a lethal neural tube defect (NTD) that forms in the first month after conception, when the top end of the neural tube should close. Ultrasound? can detect typical signs as early as the late first trimester. Radiopaedia+2CDC Archive+2

ANE syndrome is a genetic condition that starts in childhood. Children are usually born looking well, but develop scalp hair loss or very thin hair (often eyebrows/eyelashes too), slow learning or developmental delay, and movement or balance problems that slowly progress (for example, stiffness?, spasticity, ataxia, or dystonia). Many also have pituitary hormone problems, such as low growth hormone, low thyroid? hormone from the pituitary (central hypothyroidism?), low sex hormones (hypogonadotropic hypogonadism), and sometimes adrenal hormone problems. Because the pituitary controls many glands, several hormones can be low together (called combined pituitary hormone deficiency). Some people also have hearing loss, dental or nail differences, and bone fragility due to long-standing hormone shortage. Doctors confirm the diagnosis? with genetic testing showing variants in RBM28 and by testing hormone levels and brain/nerve function. Treatment focuses on hormone replacement, rehabilitation?, assistive devices, nutrition, mental-health support, and family education.

Pathophysiology

RBM28 helps build the cell’s protein factories (ribosomes) inside the nucleolus. When RBM28 does not work, fast-growing or highly specialized tissues are most vulnerable. Hair follicles cannot cycle normally → alopecia. Pituitary cells that release hormones are sensitive to ribosome stress → low growth, thyroid?, sex (and sometimes adrenal) hormones. Neurons and their support cells need stable protein production for growth, myelination, and synaptic repair → progressive neurologic problems. The result is a multisystem ribosomopathy: hair/ectodermal changes, combined pituitary hormone deficiency, and neurodevelopmental/motor impairment.

Key idea in very simple words: the skull does not form → the brain is left unprotected → the brain is damaged and then largely lost. This stepwise change is why it is called a “sequence.” Radiopaedia

Other names

• Acrania–anencephaly sequence (AAS)

• Exencephaly–anencephaly sequence

• Acrania–exencephaly–anencephaly sequence (AEAS) — the full term

• Anencephaly (the final stage of the sequence)

• Craniorachischisis (an extreme form when the skull and spine are both open) Radiopaedia+1

Types

There are two useful ways to think about “types”:

1. By stage in the sequence

• Acrania: skull bones absent; brain initially present but unprotected.

• Exencephaly: brain protrudes outside, irregular and uncovered.

• Anencephaly: most of the brain and skull are absent; a thin vascular tissue called area cerebrovasculosa may remain. Radiopaedia+1

2. By anencephaly pattern

• Meroanencephaly: partial absence of brain and skull; some tissue remains.

• Holoanencephaly: nearly complete absence of the brain (most common).

• Craniorachischisis: anencephaly plus an open spine (most severe). CDC Archive+2PubMed+2

Causes and risk factors

In real life, AEAS is usually multifactorial: genes + environment + chance. Some items below are risks rather than guaranteed causes.

1. Failure of the anterior neuropore to close (the basic cause). The top end of the neural tube should close around week 4; if it does not, anencephaly results. CDC Archive

2. Folate (folic acid) deficiency. Low folate before and in very early pregnancy increases NTD risk; periconceptional folic acid prevents many cases. CDC+1

3. Maternal vitamin B12 deficiency. Low B12 is independently linked to higher NTD risk. PMC

4. Pre-existing (pregestational) insulin? is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।" data-rx-term="diabetes" data-rx-definition="Diabetes is a condition where blood sugar stays too high because insulin is low or not working well. সহজ বাংলা: রক্তে চিনি বেশি থাকার রোগ।">diabetes?. Hyperglycemia? in early pregnancy raises NTD risk. PMC

5. Maternal obesity. Obesity nearly doubles NTD risk in meta-analyses. AJOG

6. Maternal hyperthermia (high body temperature) in early pregnancy. Fever?, hot tubs, or heat exposure increase NTD risk. Lippincott Journals

7. Valproate exposure (antiepileptic). Strong teratogen with increased NTD risk, including anencephaly. New England Journal of Medicine

8. Carbamazepine and some other antiseizure drugs. Also associated with higher NTD risk (less than valproate). ScienceDirect

9. Folate-antagonist medicines (e.g., methotrexate). Interfere with folate pathways; linked to NTDs. ScienceDirect

10. Trimethoprim-sulfamethoxazole around conception. Antifolate effect; studies report increased NTD risk. PMC

11. Genetic variants affecting cilia (e.g., Meckel–Gruber syndrome). Some syndromes include anencephaly among possible features. Frontiers

12. Single-gene defects in Hedgehog signaling (e.g., HHAT). Shown in animal models to cause acrania and severe craniofacial defects. PMC

13. Chromosomal abnormalities (e.g., trisomy 13 or 18) in a minority of cases. These aneuploidies occasionally co-occur with anencephaly. AJOG

14. Low dietary folate or lack of fortification. Populations with limited folic acid intake have higher NTD rates. PMC

15. Low maternal education or limited access to prenatal care (indirect). Associated with lower supplement use and delayed diagnosis?. (Association discussed in risk overviews.) PubMed

16. Consanguinity or strong family history of NTDs. Recurrence risk is higher in families with prior NTD-affected pregnancy. Fetal Health Foundation

17. Amniotic band disruption sequence (rare cause of acalvaria/acrania-like defects). Mechanical disruption can mimic acrania. PubMed

18. Severe skeletal demineralization disorders (differentials that can look similar). Must be distinguished from true acrania (e.g., hypophosphatasia, OI). PMC

19. Multiple micronutrient insufficiencies (e.g., low B12 with low folate). Combined deficits may raise risk. PMC

20. Chance (sporadic events). Many cases occur without any identifiable exposure or mutation; the cause may remain unknown. Medscape

Common clinical features

Because this is a fetal condition, “symptoms” are really findings on ultrasound?, in the pregnancy, or in a live-born infant.

1. Absent skull bones (acrania). The head lacks the firm bony cover (calvarium). Radiopaedia

2. Exposed brain tissue (exencephaly). The brain is outside and irregular. ScienceDirect

3. Progression to anencephaly. With time the brain tissue degenerates and disappears. Radiopaedia

4. First-trimester “Mickey-Mouse sign.” Bilobed appearance above the face on ultrasound? when calvarium is absent. NCBI

5. Second-trimester “frog-eye sign.” Bulging orbits with absent skull. PMC

6. Echogenic amniotic fluid. Debris from exposed neural tissue increases fluid brightness. Lippincott Journals

7. Polyhydramnios. Excess amniotic fluid can develop. PMC

8. Associated spinal defect in severe cases (craniorachischisis). Open skull plus open spine. CDC Archive

9. Face often formed but eyes can appear prominent. Typical for anencephaly. Radiopaedia

10. Reduced crown-rump length or growth issues early. Seen in series describing first-trimester appearances. Wiley Online Library

11. Non-viability after birth. Most affected infants die within hours to days if live-born. Cleveland Clinic

12. Maternal anxiety and grief, medical complications from polyhydramnios (breathlessness, preterm labor risk). Reported in case literature and obstetric practice. PMC

13. Normal maternal blood pressure and routine labs (no specific maternal illness unless other conditions coexist); the key clue is imaging and AFP. CDC Archive

14. Area cerebrovasculosa on pathology. Spongy vascular tissue on the cranial surface in anencephaly. CDC Archive

15. Possible association with low B12/folate status. A risk clue rather than a symptom. PMC

Diagnostic Tests

Important: Ultrasound? is the main test. Other tests help confirm the diagnosis?, look for related problems, or support counseling. Electrodiagnostics are rarely needed.

A) Physical examination (at birth or bedside in pregnancy)

1. Newborn head and scalp exam. Obvious absence of skull and scalp with exposed tissue confirms anencephaly (if live-born). Pathology will later document findings. CDC Archive

2. Head circumference measurement (OFC). Very small or immeasurable due to missing vault; recorded for documentation and counseling. CDC Archive

3. Primitive reflex checks (Moro, suck) in live-born infants. Brainstem reflexes may be minimal or absent; survival is brief. (Clinical description in pediatric/pathology texts.) Cleveland Clinic

4. Maternal abdominal exam and fundal height. Excess fluid (polyhydramnios) may raise fundal height; prompts targeted imaging. PMC

B) “Manual” bedside assessments (limited, supportive)

5. Leopold maneuvers. Palpation may suggest unusual “softness” or shape of the presenting fetal head; not diagnostic, but may raise suspicion before imaging. (Clinical obstetrics practice; imaging confirms.) CDC Archive

6. Pelvic exam for presenting part. In labor, a soft, irregular cranial mass instead of firm skull bones may be felt; still requires imaging/pathology for diagnosis?. CDC Archive

7. Maternal perception of fetal movement (kick counts). Not a diagnostic test for AEAS, but reduced movements can accompany severe anomalies and polyhydramnios; triggers evaluation. (General obstetric surveillance principles.) CDC Archive

C) Laboratory and pathological tests

8. Maternal serum alpha-fetoprotein (MSAFP). Markedly elevated AFP in the second trimester is a classic screening? clue for open NTDs, including anencephaly. Wikipedia

9. Second-trimester multiple-marker screen (e.g., quad screen). Uses AFP among other markers to flag open NTD risk; abnormal results lead to targeted ultrasound?. Wikipedia

10. Amniotic fluid AFP (after amniocentesis). Very high levels support an open NTD diagnosis?. PMC

11. Amniotic fluid acetylcholinesterase (AChE). AChE positivity is highly suggestive of an open NTD (like anencephaly). PMC

12. Pathology examination (fetal/placental). Confirms acrania/exencephaly/anencephaly and documents area cerebrovasculosa and any associated anomalies. UPMC Pathology

13. Genetic testing (karyotype/microarray; sometimes exome). Used to check for aneuploidy or syndromic causes in selected cases; yield is generally low in isolated anencephaly but guides recurrence counseling. AJOG+1

14. Maternal red blood cell (RBC) folate and vitamin B12 levels. Not diagnostic of AEAS, but helpful to find preventable deficiencies for future pregnancy planning. World Health Organization+1

D) Electrodiagnostic tests (rare and usually not needed)

15. Antenatal fetal heart-rate monitoring (non-stress test/CTG). Sometimes used to check fetal well-being, but it does not diagnose AEAS and is rarely useful because AEAS is lethal. (General obstetric surveillance context.) CDC Archive

16. Neonatal EEG or evoked potentials (if briefly live-born). May show minimal cerebral activity; again, not required and rarely performed. (Neonatal neurology/pathology descriptions.) UPMC Pathology

E) Imaging tests (the core of diagnosis?)

17. First-trimester transvaginal ultrasound? (11–14 weeks). High-resolution TVUS detects acrania/exencephaly early; described patterns improve recognition. PubMed

18. Second-trimester detailed transabdominal ultrasound? (anomaly scan). Confirms absent skull bones and anencephaly; classic “frog-eye” appearance may be seen. PMC

19. Recognition of key ultrasound? “signs.” “Mickey-Mouse sign” (first trimester) and “beret sign” (overhanging brain mantle) help early detection. NCBI+1

20. Fetal MRI (selected cases). Helpful when the ultrasound? differential includes conditions with poor skull mineralization (e.g., severe OI or hypophosphatasia). PMC

Non-pharmacological treatments (therapies & supports)

(Concise, practical paragraphs. Your team can expand/individualize each plan.)

1. Multidisciplinary care coordination
   One lead clinician (often pediatric neurologist/endocrinologist) coordinates rehab, endocrinology, audiology, ophthalmology, dentistry, nutrition, psychology, social work, and genetics. Regular team reviews align goals, avoid conflicting advice, and track growth, hormones, bones, and function.

2. Endocrine education & sick-day rules
   Families learn hormone roles, medication timing, and signs of under/over-replacement. If adrenal involvement is suspected, teach sick-day hydrocortisone stress dosing and when to seek urgent care. Provide written action plans and medical alert identification.

3. Physiotherapy for strength, spasticity, and balance
   Daily home program plus supervised sessions target range of motion, core strength, contracture prevention, posture, and gait training. Techniques include task-specific practice, stretching, orthoses, and fall-prevention strategies to preserve mobility and independence.

4. Occupational therapy (OT) for daily living
   OT adapts feeding, dressing, writing, and computer access. Recommends seating systems, upper-limb splints, fine-motor training, and environmental modifications at home/school for safety, energy saving, and participation.

5. Speech and language therapy (SLT)
   Assesses speech clarity, language, and swallowing. Provides communication strategies (slow rate, breath control, AAC devices if needed) and dysphagia? management to lower aspiration risk and improve nutrition and social interaction.

6. Neurodevelopmental/education interventions
   Individualized education plans, special education supports, classroom accommodations (quiet seating, repetition, extra time), and cognitive-behavioral strategies. Early, structured learning improves outcomes and reduces caregiver stress.

7. Assistive mobility devices
   Ankle-foot orthoses, canes, walkers, or wheelchairs matched to goals and energy levels. Safe mobility prevents falls and fractures, supports community participation, and reduces caregiver burden.

8. Orthoses and serial casting
   For focal spasticity and contractures, lower-limb AFOs or wrist/hand splints maintain position and function; serial casting gradually lengthens tight muscles and prepares for botulinum toxin or surgery if later required.

9. Hearing support
   Regular audiology; hearing aids or FM systems for mild-to-moderate loss. Early support improves language, learning, and social development. Consider cochlear implant candidacy if severe bilateral sensorineural loss.

10. Vision care
    Eye exams address refractive error, strabismus, or cortical visual issues. Glasses, patching, or school-based visual accommodations (high-contrast materials, larger fonts) help learning and safety.

11. Nutrition & bone health counseling
    Diet rich in calcium and vitamin D, adequate protein for growth/repair, fiber for GI health, and hydration. Weight-bearing exercise and sunlight exposure support bone density when hormones are low.

12. Mental-health and caregiver support
    Screen for anxiety, depression, and caregiver tendon?. সহজ বাংলা: মাংসপেশি/টেনডনে টান।" data-rx-term="strain" data-rx-definition="A strain is injury to a muscle or tendon. সহজ বাংলা: মাংসপেশি/টেনডনে টান।">strain?. Provide counseling, peer support groups, respite resources, and social services (benefits, transport, equipment funding).

13. Sleep hygiene
    Regular schedule, light control, quiet bedtime routine, and screening? for sleep-disordered breathing (especially with hypotonia). Good sleep enhances learning, mood, and seizure? threshold.

14. Falls prevention program
    Home safety audit (lighting, rails, remove loose rugs), strength/balance training, vision correction, medication review, and hip-protectors for those at high fracture? risk.

15. Dental and oral-motor care
    Regular dental checks, fluoride, sealants, and management of enamel or dentition anomalies. OT/SLT strategies for oral-motor skills protect nutrition and speech clarity.

16. Skin and scalp care
    Gentle cleansers, emollients for dry skin, and sun protection for hairless scalp (hats, SPF). Cosmetic options include wigs or scarves to reduce psychosocial impact.

17. Bladder/bowel management
    If neurogenic bowel/bladder symptoms occur, use timed toileting, fiber/fluids, pelvic-floor strategies, and continence supports to maintain dignity and participation.

18. Community and disability services
    Early registration for disability benefits, mobility allowances, school transport, home modification grants, and vocational planning during adolescence.

19. Vaccination & infection?-prevention counseling
    Keep routine vaccines up to date. Prompt treatment of infections limits decompensation in vulnerable endocrine states and reduces hospitalization.

20. Advance care and transition planning
    Prepare for adult services: handover summaries, emergency plans, guardianship/consent issues, and supported decision-making so care remains continuous and person-centered.

Drug treatments

(Doses are typical adult starting points; pediatrics and adjustments require specialists and lab targets.)

1. Hydrocortisone (central adrenal insufficiency)
   Class: Glucocorticoid. Dose: often 15–25 mg/day in 2–3 divided doses; stress-dose during illness. Purpose: replace cortisol. Mechanism: binds glucocorticoid receptors to maintain blood pressure, glucose, and stress response. Side effects: weight gain, hypertension?, bone loss with over-replacement.

2. Fludrocortisone (if mineralocorticoid deficit is present)
   Class: Mineralocorticoid. Dose: 0.05–0.2 mg daily. Purpose: sodium retention and BP support. Mechanism: aldosterone receptor agonist. Side effects: edema, hypertension?, low potassium.

3. Levothyroxine (central hypothyroidism)
   Class: T4 thyroid hormone. Dose: ~1.6 µg/kg/day adults (titrate to free T4 in upper half of normal). Purpose: metabolic replacement. Mechanism: restores cellular thyroid action. Side effects: palpitations, bone loss if over-replaced.

4. Recombinant human growth hormone (GH)
   Class: Pituitary hormone. Dose: adults often start 0.2–0.4 mg SC daily, titrate by IGF-1 and symptoms. Purpose: body composition, bone, energy. Side effects: edema, arthralgia, glucose intolerance.

5. Testosterone (hypogonadotropic hypogonadism, males)
   Class: Androgen. Dose: transdermal 50–100 mg/day or IM 75–100 mg weekly (or 150–200 mg q2w). Purpose: puberty/sexual function, muscle/bone. Side effects: erythrocytosis, acne, infertility, prostate monitoring in adults.

6. Estrogen ± progesterone (females with HH)
   Class: Sex steroids. Dose: transdermal/PO estradiol with cyclic/progestin for uterus protection. Purpose: puberty, menses, bone, sexual health. Side effects: VTE risk (route & patient factors), breast tenderness, mood changes.

7. Desmopressin (if central diabetes insipidus occurs)
   Class: Vasopressin analog. Dose: 0.05–0.2 mg PO 1–2×/day (or intranasal/SC). Purpose: reduce excessive urination/thirst. Side effects: hyponatremia if overused.

8. Calcium + Vitamin D (adjunct for bone)
   Class: Supplements. Dose: Calcium 1000–1200 mg/day diet+pill; Vitamin D 600–800 IU/day (or individualized to reach 25-OH-D target). Purpose: bone mineralization support. Side effects: constipation (calcium), hypercalcemia if overdosed.

9. Bisphosphonates (if low bone density with fractures)
   Class: Antiresorptives (e.g., alendronate 70 mg weekly). Purpose: fracture risk reduction. Side effects: GI irritation, rare osteonecrosis of jaw/atypical femur—dental checks advised.

10. Insulin (if diabetes occurs)
    Class: Peptide hormone. Dose: individualized basal-bolus or pump. Purpose: glycemic control. Side effects: hypoglycemia, weight gain.

11. Metformin (insulin resistance/diabetes)
    Class: Biguanide. Dose: 500 mg daily → 1000 mg BID as tolerated. Purpose: lower hepatic glucose output; weight neutral. Side effects: GI upset, rare lactic acidosis (avoid in severe renal/hepatic disease).

12. Baclofen (spasticity)
    Class: GABA-B agonist. Dose: 5 mg TID → up to 20 mg TID (titrate). Purpose: reduce tone and spasms. Side effects: sedation, weakness; taper slowly.

13. Tizanidine (spasticity)
    Class: α2-agonist. Dose: 2 mg at night → 2–8 mg TID (titrate). Side effects: sedation, hypotension, dry mouth, liver enzyme rise.

14. Botulinum toxin type A (focal dystonia/spasticity)
    Class: Neurotoxin (local injection). Dose: individualized by muscle pattern every ~12 weeks. Purpose: relax overactive muscles, ease care, improve function. Side effects: local weakness, pain.

15. Levetiracetam (seizures if present)
    Class: Antiseizure. Dose: 500 mg BID → 1500 mg BID. Side effects: mood irritability, somnolence.

16. Clonazepam (myoclonus/dystonia adjunct)
    Class: Benzodiazepine. Dose: 0.25–0.5 mg HS → divided doses. Side effects: sedation, dependence; use sparingly.

17. Gabapentin (neuropathic pain)
    Class: Anticonvulsant/analgesic. Dose: 100–300 mg HS → up to 900–1200 mg TID. Side effects: dizziness, somnolence, edema.

18. Melatonin (sleep-wake support)
    Class: Hormone supplement. Dose: 1–5 mg 30–60 min before bed. Side effects: morning grogginess, vivid dreams.

19. Selective serotonin reuptake inhibitor—SSRI (anxiety/depression)
    Class: Antidepressant (e.g., sertraline 25–50 mg/day → up). Side effects: GI upset, sexual dysfunction; monitor for activation in youth.

20. Acetaminophen or NSAIDs (pain/contracture aches)
    Class: Analgesics. Dose: per label/clinician advice; avoid chronic high-dose NSAIDs with bone concerns or GI/renal risk. Side effects: liver toxicity (acetaminophen overdose), GI/renal (NSAIDs).

Dietary molecular supplements

(Use only with clinician approval; aim for lab-guided correction rather than routine megadoses.)

1. Vitamin D3 – supports bone, muscle, and immunity. Typical 600–800 IU/day, or tailored to reach target blood level. Mechanism: nuclear receptor actions improving calcium absorption and bone mineralization.

2. Calcium – meet total 1000–1200 mg/day from food + pill if needed. Mechanism: provides substrate for bone; works best with vitamin D and weight-bearing activity.

3. Omega-3 fatty acids (EPA/DHA) – 1–2 g/day may help triglycerides and general inflammation; not disease-specific. Mechanism: membrane and eicosanoid effects.

4. Iron (if deficient) – dose per ferritin and hemoglobin; improves fatigue and cognition when deficiency exists. Mechanism: hemoglobin and mitochondrial enzymes.

5. Vitamin B12 (if low) – oral 1 mg/day or injections; supports myelin and blood cells. Mechanism: cofactor for DNA/myelin synthesis.

6. Folate (if low) – 0.4–1 mg/day; supports DNA synthesis and red cells. Correct B12 first to avoid neuropathy masking.

7. Zinc (short course if low) – supports hair/skin and immune enzymes. Avoid long-term high doses that lower copper.

8. Biotin – often used for hair; evidence for genetic alopecia is limited. If tried, use modest doses and monitor.

9. Magnesium – may aid muscle relaxation and sleep in deficiency; check renal function and avoid high doses causing diarrhea.

10. Protein supplementation – whey/food-based protein to meet daily protein targets when appetite is low; supports growth, muscle, and wound healing.

Immunity-booster / regenerative / stem-cell drugs

There are no proven immune-booster or stem-cell drugs that treat ANE syndrome. Below are items patients often ask about—explained with clear guidance:

1. Mesenchymal stem-cell infusions – Not approved for ANE. Risks include infection, clots, ectopic tissue. Use only in regulated clinical trials.

2. Exosome products – Unapproved/unsafe outside trials. Quality and dosing are unstandardized; potential contamination risks.

3. Platelet-rich plasma (PRP) for scalp – Evidence is for autoimmune alopecia areata; does not reverse genetic alopecia from RBM28. Discuss expectations; avoid costly, unproven courses.

4. Thymosin-α1 or “immune peptides” – No credible evidence in ANE; avoid off-label “immune boosters.”

5. Recombinant growth factors/serums for hair – Cosmetic benefits are limited; do not change underlying genetic cause.

6. Hematopoietic stem-cell transplantation (HSCT) – Treats certain blood/immune diseases; no indication in ANE and carries major risks. Not recommended.

Surgeries

1. Cochlear implant – for severe bilateral sensorineural hearing loss when hearing aids fail; improves access to language and education.

2. Orthopedic tendon-lengthening or derotation – for fixed contractures or severe torsion impairing care/walking after conservative therapy and botulinum toxin.

3. Selective dorsal rhizotomy or intrathecal baclofen pump – in carefully selected spasticity with refractory tone causing pain/care difficulty.

4. Dental/craniofacial procedures – address enamel defects/malocclusion; improve chewing, speech, and self-image.

5. Gastrostomy tube – if unsafe swallowing or severe under-nutrition despite therapy; protects lungs and growth.

Preventions

1. Keep hormone replacements consistent and monitored.

2. Carry medical alert and sick-day plan (especially if adrenal risk).

3. Vaccinations on time; prompt infection care.

4. Fall-proof home; use appropriate mobility devices.

5. Weight-bearing activity + Ca/Vit D for bones.

6. Regular dental, eye, and hearing checks.

7. Safe swallowing routines to prevent aspiration.

8. Sleep schedule and screen-for apnea.

9. Mental-health check-ins for family and patient.

10. Early transition planning to adult care.

When to see doctors (red flags)

1. Fever, vomiting, or severe illness when adrenal insufficiency is possible (urgent steroid stress dosing).
2. New or worsening seizures, severe headache, or sudden weakness.
3. Rapid weight loss, dehydration, or very high/low blood sugars
4. Persistent vomiting or aspiration/choking spells.
5. Recurrent falls, new fractures, or painful contractures.
6. Suicidal thoughts, severe behavior change, or caregiver burnout.

What to eat and what to avoid

1. Eat more: calcium-rich foods (milk/yogurt/cheese or fortified alternatives), leafy greens, beans, nuts/seeds, eggs/fish/lean meats for protein, whole grains, colorful fruits/vegetables, olive-oil-based fats, and enough water.
2. Limit/avoid: excess sugary drinks and ultra-processed snacks, heavy alcohol (adults), smoking/vaping, very high-salt foods if BP issues, and fad “immune-boosting” supplements with no evidence. If diabetes is present, follow a balanced, lower-glycemic meal plan set by your clinician.

Frequently asked questions

1. Is there a cure? Not yet. Treatment replaces missing hormones and supports function.

2. Will hair regrow? Genetic alopecia from RBM28 rarely regrows; use protective scalp care and cosmetic options.

3. Is this the same as Woodhouse–Sakati syndrome? No—overlap in symptoms, but different gene and inheritance.

4. Can children attend regular school? Many do with supports, individualized education plans, and therapy services.

5. Will problems get worse? Neurologic features can be slowly progressive; proactive rehab slows complications.

6. Can my child play sports? Yes, with safety adaptations; physiotherapy can guide choices.

7. Are vaccines safe? Yes—follow routine schedules unless your clinician advises otherwise.

8. Will hormone therapy stunt natural glands? Replacement restores what is missing; doses are adjusted to labs and growth.

9. Can special diets cure ANE? No. Healthy nutrition supports bones, energy, and immunity but does not change genes.

10. Are stem-cell clinics helpful? No proven benefit in ANE; potential harms. Avoid outside trials.

11. What about JAK inhibitors for hair? These help autoimmune alopecia areata, not genetic RBM28 alopecia.

12. How often are checkups? Typically every 3–6 months in childhood, then as needed; more often during changes.

13. Can adults work? Many can with accommodations, assistive tech, and vocational support.

14. How do we plan for the future? Start transition planning by early teens; organize benefits, equipment, and education/work goals.

15. Where can families find support? Genetics clinics, rare-disease organizations, disability services, and local rehab networks.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 17, 2025.